Polygonum orientale L. Alleviates Myocardial Ischemia-Induced Injury via Activation of MAPK/ERK Signaling Pathway

被引:4
作者
Fu, Changli [1 ,2 ]
Wang, Mingjin [1 ,2 ]
Lu, Yuan [3 ]
Pan, Jie [1 ]
Li, Yueting [3 ]
Li, Yongjun [1 ]
Wang, Yonglin [3 ]
Wang, Aimin [1 ]
Huang, Yong [3 ]
Sun, Jia [3 ]
Liu, Chunhua [1 ]
机构
[1] Guizhou Med Univ, Engn Res Ctr Dev & Applicat Ethn Med & TCM, State Key Lab Funct & Applicat Med Plants, Minist Educ, Guiyang 550004, Peoples R China
[2] Guizhou Med Univ, Sch Pharm, Guiyang 550004, Peoples R China
[3] Guizhou Med Univ, Guizhou Prov Key Lab Pharmaceut, Guiyang 550004, Peoples R China
来源
MOLECULES | 2023年 / 28卷 / 09期
基金
中国国家自然科学基金;
关键词
Polygonum orientale L; myocardial ischemia; MAPK signaling pathway; NITRIC-OXIDE; REPERFUSION INJURY; ESI-MS/MS; HEART; ISCHEMIA/REPERFUSION; INHIBITION; APOPTOSIS; ERK1/2;
D O I
10.3390/molecules28093687
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although Polygonum orientale L. (PO) has a beneficial effect on treatment of myocardial ischemia (MI), its mechanism remains unclear. This study aimed to explore the pharmacological mechanism of PO against MI through MAPK signaling pathways. Firstly, the therapeutic effect of PO was evaluated for treatment of MI mice. Using Western blot and immunohistochemistry, the influence of PO on MAPK signaling pathways and cell apoptosis was investigated. Subsequently, one key pathway (ERK) of MAPK signaling pathways was screened out, on which PO posed the most obvious impact. Finally, an inhibitor of ERK1/2 was utilized to further verify the regulatory effect of PO on the MAPK/ERK signaling pathway. It was found that PO could reduce the elevation of the ST segment; injury of heart tissue; the activity of LDH, CK, NOS, cNOS and iNOS and the levels of NO, BNP, TNF-a and IL-6. It is notable that PO could significantly modulate the protein content of p-ERK/ERK in mice suffering from MI but hardly had an effect on p-JNK/JNK and p-p38/p38. Additionally, the expressions of bax, caspase3 and caspase9 were inhibited in heart tissue in the PO-treated group. To evaluate whether ERK1/2 inhibitor (PD98059) could block the effect of PO on treatment of MI, both PO and PD98059 were given to mice with MI. It was discovered that the inhibitor indeed could significantly reverse the regulatory effects of PO on the above indicators, indicating that PO could regulate p-ERK/ERK. This study provides experimental evidence that PO extenuates MI injury, cardiomyocyte apoptosis and inflammation by activating the MAPK/ERK signaling pathway.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Iguratimod Alleviates Myocardial Ischemia/Reperfusion Injury Through Inhibiting Inflammatory Response Induced by Cardiac Fibroblast Pyroptosis via COX2/NLRP3 Signaling Pathway
    Zhang, Mian
    Lei, Yi-Shan
    Meng, Xiao-Wen
    Liu, Hua-Yue
    Li, Lin-Gui
    Zhang, Jun
    Zhang, Jia-Xin
    Tao, Wen-Hui
    Peng, Ke
    Lin, Jun
    Ji, Fu-Hai
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [42] Propofol alleviates hepatic ischemia/reperfusion injury via the activation of the Sirt1 pathway
    Liu, Yi
    Du, Xiaohong
    Zhang, Shouhua
    Liu, Xiuxia
    Xu, Guohai
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (11): : 10959 - 10968
  • [43] Atorvastatin protects against cyclophosphamide-induced thyroid injury in rats via modulation of JNK/ERK/p38 MAPK signaling pathway
    Abdelzaher, Walaa Yehia
    Abdel-Gaber, Seham A.
    Fawzy, Michael Atef
    Ali, Abdel Hamid Sayed Abo Bakr
    Attya, Mina Ezzat
    Geddawy, Ayman
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 124
  • [44] SPRED2 deficiency may lead to lung ischemia-reperfusion injury via ERK1/2 signaling pathway activation
    Okada, Masanori
    Yamane, Masaomi
    Yamamoto, Sumiharu
    Otani, Shinji
    Miyoshi, Kentaroh
    Sugimoto, Seiichiro
    Matsukawa, Akihiro
    Toyooka, Shinichi
    Oto, Takahiro
    Miyoshi, Shinichiro
    SURGERY TODAY, 2018, 48 (12) : 1089 - 1095
  • [45] The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway
    Liu, Zhenling
    Chen, Ji-Mei
    Huang, Huanlei
    Kuznicki, Michelle
    Zheng, Shaoyi
    Sun, Wanqing
    Quan, Nanhu
    Wang, Lin
    Yang, Hui
    Guo, Hui-Ming
    Li, Ji
    Zhuang, Jian
    Zhu, Ping
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (03): : 122 - 130
  • [46] Erythropoietin alleviates acute lung injury induced by ischemia-reperfusion through blocking p38 MAPK signaling
    Jia, Ling
    Cui, Wenjing
    Chen, Jiao
    Yang, Jinghui
    Xue, Xiang
    Cai, Jianqin
    Zhao, Wei
    Gao, Wei
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2021, 40 (12_SUPPL) : S593 - S602
  • [47] QiShenYiQi dripping pill alleviates myocardial ischemia-induced ferroptosis via improving mitochondrial dynamical homeostasis and biogenesis
    Wu, Lingling
    Fan, Zhaoyang
    Gu, Lifei
    Liu, Jincheng
    Cui, Zekun
    Yu, Boyang
    Kou, Junping
    Li, Fang
    JOURNAL OF ETHNOPHARMACOLOGY, 2023, 308
  • [48] Biochanin A Alleviates Cerebral Ischemia/Reperfusion Injury by Suppressing Endoplasmic Reticulum Stress-Induced Apoptosis and p38MAPK Signaling Pathway In Vivo and In Vitro
    Guo, Min-min
    Qu, Sheng-biao
    Lu, Hui-ling
    Wang, Wen-bo
    He, Mu-Liang
    Su, Jian-Lin
    Chen, Jian
    Wang, Yong
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [49] Apigenin alleviates oxidative stress-induced myocardial injury by regulating SIRT1 signaling pathway
    Xu, Kun
    Yang, Yao
    Lan, Ming
    Wang, Jiannan
    Liu, Bing
    Yan, Mingjing
    Wang, Hua
    Li, Wenlin
    Sun, Shenghui
    Zhu, Kaiyi
    Zhang, Xiyue
    Hei, Mingyan
    Huang, Xiuqing
    Dou, Lin
    Tang, Weiqing
    He, Qing
    Li, Jian
    Shen, Tao
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 944
  • [50] Oxytocin ameliorates high glucose- and ischemia/reperfusion-induced myocardial injury by suppressing pyroptosis via AMPK signaling pathway
    Yao, Mengran
    Wang, Zhuoran
    Jiang, Leyu
    Wang, Lingyan
    Yang, Yuqiao
    Wang, Quan
    Qian, Xi
    Zeng, Weijun
    Yang, Wei
    Liang, Rongbi
    Qian, Jinqiao
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 153